Eton Pharma Acquires Galzin, FDA-Approved Treatment for Wilson Disease

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate).

“This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra rare patient populations. Galzin is a critical medication for patients with Wilson disease, and we look forward to supporting these patients with our comprehensive Eton Cares patient support programme,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Galzin is FDA-approved as a maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is estimated that less than 5,000 patients in the United States are currently being treated for Wilson disease.

Eton expects to assume the commercialization of the product in the United States in the first quarter of 2025 with its metabolic sales force supporting healthcare professionals who treat Wilson disease. Once available, Eton plans to offer the product through its Eton Cares patient support program that provides high-touch, personalized service tailored for rare disease patients and their providers. The program will offer a $0 co-pay for all qualified commercial patients, provide prescription fulfillment, insurance benefits investigation, educational support, and other services designed to help patients access treatment.

As part of the transaction, Eton has also acquired European rights to the product, where it is commercialized under the tradename Wilzin by a third party. Under an existing distribution agreement, Eton will continue to supply the product to the third party and the third party is responsible for all commercialization activities in Europe.

Stifel served as exclusive financial advisor to Eton on the transaction.

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has six commercial rare disease products: Increlex, Alkindi Sprinkle, Pku Golike, Carglumic acid, Betaine Anhydrous, and Nitisinone.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!